Focus: Unicycive Therapeutics is a public-stage biotechnology company focused on kidney disease treatments, headquartered in Mountain View, CA. The company operates as a highly focused nephrology-stage player with a minimal commercial footprint.
Profile data last refreshed 14h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow Unicycive Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Unicycive Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Help build intelligence for Unicycive Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Class Action Lawsuit Filed: Unicycive Therapeutics, Inc. (UNCY) - Join by November 2, 2026 - Contact Levi & Korsinsky - ACCESS Newswire
Class Action Lawsuit Filed: Unicycive Therapeutics, Inc. (UNCY) - Join by November 2, 2026 - Contact Levi & Korsinsky ACCESS Newswire
DEADLINE ALERT for Hims & Hers Health, Inc. (HIMS), - GlobeNewswire
DEADLINE ALERT for Hims & Hers Health, Inc. (HIMS), GlobeNewswire
UNCY URGENT DEADLINE: Unicycive Therapeutics, Inc. Investors Have Until November 2nd to Contact Bragar Eagel & Squire, P.C. Seeking Lead Plaintiff Role - mykxlg.com
UNCY URGENT DEADLINE: Unicycive Therapeutics, Inc. Investors Have Until November 2nd to Contact Bragar Eagel & Squire, P.C. Seeking Lead Plaintiff Role mykxlg.com
UNCY URGENT DEADLINE: Unicycive Therapeutics, Inc. - GlobeNewswire
UNCY URGENT DEADLINE: Unicycive Therapeutics, Inc. GlobeNewswire
Unicycive Therapeutics: 95% Upside Priced Against A Wall Of Dilution And Regulatory Risk - Seeking Alpha
Unicycive Therapeutics: 95% Upside Priced Against A Wall Of Dilution And Regulatory Risk Seeking Alpha
Unicycive Therapeutics stock faces March FDA decision after NDA acceptance - ad-hoc-news.de
Unicycive Therapeutics stock faces March FDA decision after NDA acceptance ad-hoc-news.de
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Shareholder litigation, double regulatory rejection, and acute cash burn create high operational and legal risk; employment severance risk is elevated.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 6 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo